Tempero M - Search Results

1

Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.

Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL. Ko AH, et al. Among authors: tempero m. Mol Ther. 2020 Nov 4;28(11):2367-2378. doi: 10.1016/j.ymthe.2020.07.017. Epub 2020 Jul 21. Mol Ther. 2020. PMID: 32730744 Free PMC article.

2

Current and future strategies for combined-modality therapy in pancreatic cancer.

Ko AH, Tempero MA. Ko AH, et al. Curr Oncol Rep. 2002 May;4(3):202-12. doi: 10.1007/s11912-002-0017-z. Curr Oncol Rep. 2002. PMID: 11937010 Review.

3

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.

Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Ko AH, et al. Among authors: tempero ma. Br J Cancer. 2005 Jul 25;93(2):195-9. doi: 10.1038/sj.bjc.6602687. Br J Cancer. 2005. PMID: 15999098 Free PMC article. Clinical Trial.

4

Systemic therapy for pancreatic cancer.

Ko AH, Tempero MA. Ko AH, et al. Semin Radiat Oncol. 2005 Oct;15(4):245-53. doi: 10.1016/j.semradonc.2005.06.001. Semin Radiat Oncol. 2005. PMID: 16183478 Review.

5

Treatment of metastatic pancreatic cancer.

Ko AH, Tempero MA. Ko AH, et al. J Natl Compr Canc Netw. 2005 Sep;3(5):627-36. doi: 10.6004/jnccn.2005.0036. J Natl Compr Canc Netw. 2005. PMID: 16194454 Review.

6

Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Ko AH, et al. J Clin Oncol. 2006 Jan 20;24(3):379-85. doi: 10.1200/JCO.2005.01.8267. Epub 2005 Dec 12. J Clin Oncol. 2006. PMID: 16344320 Clinical Trial.

7

A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.

Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. Ko AH, et al. Among authors: tempero ma. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):809-16. doi: 10.1016/j.ijrobp.2007.01.005. Epub 2007 Mar 23. Int J Radiat Oncol Biol Phys. 2007. PMID: 17363191 Clinical Trial.

8

Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Ko AH, et al. Cancer Invest. 2008 Feb;26(1):47-52. doi: 10.1080/07357900701681483. Cancer Invest. 2008. PMID: 18181045 Clinical Trial.

9

A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?

Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. Ko AH, et al. Invest New Drugs. 2008 Oct;26(5):463-71. doi: 10.1007/s10637-008-9127-2. Epub 2008 Apr 1. Invest New Drugs. 2008. PMID: 18379729 Clinical Trial.

10

Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.

Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Wong D, et al. Pancreas. 2008 Oct;37(3):269-74. doi: 10.1097/MPA.0b013e31816d8185. Pancreas. 2008. PMID: 18815548

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

290 results

Search Page

Filters